Efficacy and safety of low-dose everolimus and tacrolimus in kidney transplant recipients: A retrospective study

doi:10.5500/wjt.v16.i2.118249

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

(26)

(30)

(0)

(42)

(666)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Transplant. Jun 18, 2026; 16(2): 118249
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118249

Table 3 Quantitative analysis: Proteinuria levels before and after initiation of everolimus

Mean urinary protein (mg/dL)		SD
Before everolimus	87.84	141.60
After everolimus	64.31	117.44

P < 0.05.

Full Size Table

Citation: Pahari DK, Pahari H. Efficacy and safety of low-dose everolimus and tacrolimus in kidney transplant recipients: A retrospective study. World J Transplant 2026; 16(2): 118249
URL: https://www.wjgnet.com/2220-3230/full/v16/i2/118249.htm
DOI: https://dx.doi.org/10.5500/wjt.v16.i2.118249

Pahari DK, Pahari H. Efficacy and safety of low-dose everolimus and tacrolimus in kidney transplant recipients: A retrospective study. World J Transplant 2026; 16(2): 118249 [PMID: 42281862 DOI: 10.5500/wjt.v16.i2.118249]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.